The Dermatomyositis drugs in development market research report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dermatomyositis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued products.
GlobalData tracks 38 drugs in development for Dermatomyositis by 35 companies/universities/institutes. The top development phase for Dermatomyositis is phase ii with 12 drugs in that stage. The Dermatomyositis pipeline has 34 drugs in development by companies and four by universities/ institutes. Some of the companies in the Dermatomyositis pipeline products market are: Pfizer, Nanjing Bioheng Biotech and Argenx.
The key targets in the Dermatomyositis pipeline products market include B Lymphocyte Antigen CD19, Non Receptor Tyrosine Protein Kinase TYK2, and Proteasome Subunit Beta Type 8.
The key mechanisms of action in the Dermatomyositis pipeline product include Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor with two drugs in Phase III. The Dermatomyositis pipeline products include 11 routes of administration with the top ROA being Intravenous and ten key molecule types in the Dermatomyositis pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.
Dermatomyositis overview
Dermatomyositis is a rare inflammatory disease characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.
For a complete picture of Dermatomyositis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
